R

ise and shine, everyone, another busy day is on the way. Our journey is made more tolerable today thanks to a bright and shiny sun enveloping the otherwise chilly Pharmalot campus. To keep warm, yes, we are quaffing a few welcome cups of stimulation, alternating between peppermint mocha and blueberry. Feel free to join us. What have you got to lose? Meanwhile, here are some tidbits. Hope you have a smashing day and, as always, we would like to remind you that we accept tips, encrypted messages, and secret dossiers from overseas …

Preliminary research suggesting some diabetes patients may be injecting medicine that has partially disintegrated is causing concern even as serious questions are raised about the research itself, the Associated Press writes. The study author, a pharmacist, bought 18 vials of insulin at several pharmacies and found, on average, the vials had less than half of what was listed on the label and none met a minimum standard. But the methods used to test the insulin are being questioned, and insulin makers, patient advocate groups, and diabetes experts say patients would be getting sick if the findings were accurate. The study was published in the Journal of Diabetes Science & Technology.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to pharmvet1 Cancel reply

Please enter your name.
Please enter a comment.

  • Jim Wilson should know something about gene therapy safety, given that he killed the first patient, Jesse Gelsinger, who had ornithine transcarbamylase deficiency with the replacement gene in an adenoviral vector that destroyed his liver. The irony is that Gelsinger could have survived simply by putting him on a protein sparing diet.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.